TY - T1的显著的性别差异在临床疾病活动和多发性硬化症的严重性:丹麦全国队列研究(S40.005) JF -神经学乔-神经学六世- 98 - 18补充SP - 1939 AU -梅林达Magyari盟Nils Koch-Henriksen Y1 - 2022/05/03 UR - http://n.neurolo首页gy.org/content/98/18_Supplement/1939.abstract N2 -目的:分析性别差异在复发疾病活动的频率和发展残疾某些残疾里程碑的时间在一个几乎完整的全国性的多发性硬化(MS)患者超过25年。背景:女士的发病率在女性明显高于男性,和几家大型流行病学调查显示女性男性性别比例不断增加。除了这种性别失衡,一些研究表明,男性和女性的不同演化。女士设计/方法:所有丹麦公民与发病relapsing-onset女士自1996年以来经历了疾病修饰治疗,一直跟随在丹麦的神经学部门做一次或每年访问评估残疾的扩大残疾状态量表评分和记录的复发。首页丹麦女士注册的通知与这些数据是强制性的质量评估项目的一部分的卫生当局。数据分析了广义线性模型基于倾向分数加权后的女性给予所有其他人口统计学和临床基线变量。时间端点被加权Cox回归分析。结果:我们包括8922名患者中,2780名男性和6142名女性被观察到平均8.57年(差4.08—-12.22)。年化利率突破复发的女性对男性0.186和0.225;p & lt;0.001。 With women as reference the hazard ratios in men for reaching EDSS 4 and 6 were 1.39 (p<0.001) and 1.49 (p<0.001), respectively.Conclusions: This follow-up study, complete from onset, gave strong evidence for more inflammatory disease activity in women particularly with younger age, and more neurodegeneration in men with shorter time to serious disability.Disclosure: Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Magyari has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Magyari has received research support from The Danish MS Society. The institution of Dr. Magyari has received research support from Biogen. The institution of Dr. Magyari has received research support from Novartis. The institution of Dr. Magyari has received research support from Roche. The institution of Dr. Magyari has received research support from Merck. The institution of Dr. Magyari has received research support from Sanofi. Dr. Koch-Henriksen has nothing to disclose. ER -